Construction and Selection of GLP-1 Receptor Agonist Drug Evaluation System
Objective A comprehensive evaluation of GLP-1 receptor agonist(GLP-1RA)was conducted using the Quick Guideline for Drug Evaluation and Selection in Chinese Medical Institutions(the Second Edition)(for short:Quick Guideline),to improve the quality of hospital pharmaceutical services,and establish a standard,appropriate,and standardized reference basis and work guidance for the comprehensive clinical evaluation and selection of drugs in hospitals.Methods Referring to the"Quick Guideline",the drugs included in the evaluation were quantified on four dimensions of clinical properties(efficiency and safety),pharmaceutical properties,economy and others,to develop a comprehensive clinical evaluation system for actual drugs in hospitals.Conduct an evaluation and record the results.Results Smegglutide 77.4 points,liraglutide 76.6 points,dulaglutide 73.9 points,polyethylene glycol losenatide 72.7 points,lisenatide 69.4 points,exenatide 67.8 points,and benarutide 65.5 points.Smeglutide,liraglutide,dulaglutide and polyethylene glycol losenside were strongly recommended,while liraglutide,exenatide,and benarutide were weakly recommended.Conclusion GLP-1 receptor agonist is one of the first-line hypoglycemic drugs for diabetes patients with cardiovascular disease risk factors,Various GLP-1RA offer distinct clinical advantages.Utilizing the"Quick Guideline"for oral anticoagulant selection and evaluation can offer visual evidence for hospital drug selection and promote the scientific,rational,and safe use of drugs in clinical management.
GLP-1 receptor agonistDrug evaluation systemPractice of drug selection
NETL
NSTL
万方数据
